Evidence map›Paper›PMID 41965870›Full record

ArticleEMBO molecular medicine2026

Proteome profiles of esophageal squamous cell carcinoma tie mitochondrial complex I to immunotherapy.

Fahan Ma, Yan Li, Chan Xiang, Bing Wang, Jie Lv, Zhanxian Shang, Weiguang Zhang, Zhaoyu Qin, Yan Pu, Kai Li and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EMBO molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Fahan Ma *Clinical Research Center for Cell-based Immunotherapy of Shanghai Pudong Hospital, Fudan University Pudong Medical Center, State Key Laboratory of Genetics and Development of Complex Phenotypes, School of Life Sciences, Human Phenome Institute, Fudan University, Shanghai, China.
Yan Li *Department of Laboratory Medicine, Institute of Laboratory Medicine, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.ORCID 0000-0001-9041-7675
Chan Xiang *Department of Pathology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Bing Wang *Clinical Research Center for Cell-based Immunotherapy of Shanghai Pudong Hospital, Fudan University Pudong Medical Center, State Key Laboratory of Genetics and Development of Complex Phenotypes, School of Life Sciences, Human Phenome Institute, Fudan University, Shanghai, China.
Jie Lv *Key Laboratory of Spine and Spinal Cord Injury Repair and Regeneration of Ministry of Education, Orthopaedic Department of Tongji Hospital, School of Life Sciences and Technology, Tongji University, Shanghai, China.
Zhanxian Shang *Department of Pathology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Weiguang Zhang *Department of Thoracic Surgery, Fujian Medical University Union Hospital, Fuzhou, China.
Zhaoyu QinClinical Research Center for Cell-based Immunotherapy of Shanghai Pudong Hospital, Fudan University Pudong Medical Center, State Key Laboratory of Genetics and Development of Complex Phenotypes, School of Life Sciences, Human Phenome Institute, Fudan University, Shanghai, China.
Yan PuClinical Research Center for Cell-based Immunotherapy of Shanghai Pudong Hospital, Fudan University Pudong Medical Center, State Key Laboratory of Genetics and Development of Complex Phenotypes, School of Life Sciences, Human Phenome Institute, Fudan University, Shanghai, China.
Kai LiClinical Research Center for Cell-based Immunotherapy of Shanghai Pudong Hospital, Fudan University Pudong Medical Center, State Key Laboratory of Genetics and Development of Complex Phenotypes, School of Life Sciences, Human Phenome Institute, Fudan University, Shanghai, China.
Jinzhi WeiDepartment of Pathology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Su-Bei TanClinical Research Center for Cell-based Immunotherapy of Shanghai Pudong Hospital, Fudan University Pudong Medical Center, State Key Laboratory of Genetics and Development of Complex Phenotypes, School of Life Sciences, Human Phenome Institute, Fudan University, Shanghai, China.
Jinwen FengClinical Research Center for Cell-based Immunotherapy of Shanghai Pudong Hospital, Fudan University Pudong Medical Center, State Key Laboratory of Genetics and Development of Complex Phenotypes, School of Life Sciences, Human Phenome Institute, Fudan University, Shanghai, China.
Haohua TengDepartment of Pathology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Peipei ZhangDepartment of Thoracic Surgery, Fujian Medical University Union Hospital, Fuzhou, China.
Jiaying DengDepartment of Radiation Oncology, Departments of Thoracic Surgery and State Key Laboratory of Genetic Engineering, Fudan University Shanghai Cancer Center, Shanghai, China.
Yunzhi WangClinical Research Center for Cell-based Immunotherapy of Shanghai Pudong Hospital, Fudan University Pudong Medical Center, State Key Laboratory of Genetics and Development of Complex Phenotypes, School of Life Sciences, Human Phenome Institute, Fudan University, Shanghai, China.
Chao ZhangDepartment of Radiation Oncology, Departments of Thoracic Surgery and State Key Laboratory of Genetic Engineering, Fudan University Shanghai Cancer Center, Shanghai, China.
Sha TianClinical Research Center for Cell-based Immunotherapy of Shanghai Pudong Hospital, Fudan University Pudong Medical Center, State Key Laboratory of Genetics and Development of Complex Phenotypes, School of Life Sciences, Human Phenome Institute, Fudan University, Shanghai, China.ORCID 0000-0003-4407-8873
Guichao LiDepartment of Radiation Oncology, Departments of Thoracic Surgery and State Key Laboratory of Genetic Engineering, Fudan University Shanghai Cancer Center, Shanghai, China.
Mingqiang KangDepartment of Thoracic Surgery, Fujian Medical University Union Hospital, Fuzhou, China. 9199115045@fjmu.edu.cn.
Changsheng DuKey Laboratory of Spine and Spinal Cord Injury Repair and Regeneration of Ministry of Education, Orthopaedic Department of Tongji Hospital, School of Life Sciences and Technology, Tongji University, Shanghai, China. duchangsheng@tongji.edu.cn.ORCID 0000-0002-7922-9785
Yuchen HanDepartment of Pathology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. ychan@cmu.edu.cn.
Chen DingClinical Research Center for Cell-based Immunotherapy of Shanghai Pudong Hospital, Fudan University Pudong Medical Center, State Key Laboratory of Genetics and Development of Complex Phenotypes, School of Life Sciences, Human Phenome Institute, Fudan University, Shanghai, China. chend@fudan.edu.cn.ORCID 0000-0001-8673-3464

Funding

MOST | National Key Research and Development Program of China (NKPs) 2022YFA1303200MOST | National Key Research and Development Program of China (NKPs) 2022YFA1303201MOST | National Natural Science Foundation of China (NSFC) 31972933MOST | National Natural Science Foundation of China (NSFC) 32201212MOST | National Natural Science Foundation of China (NSFC) 32201215MOST | National Natural Science Foundation of China (NSFC) 32301236MOST | National Natural Science Foundation of China (NSFC) 32330062MOST | National Natural Science Foundation of China (NSFC) 32471498MOST | National Natural Science Foundation of China (NSFC) 82003154MOST | National Natural Science Foundation of China (NSFC) 82372669Science and Technology Commission of Shanghai Municipality (STCSM) 2023SHZDZX02Shanghai Sailing Program 23YF1402800STCSM | Program of Shanghai Academic Research Leader (Shanghai Academic Research Leader) 22XD1420100the Fudan original research personalized support project, and the China Postdoctoral Science Foundation 2024T170177the Major Project of Special Development Funds of Zhangjiang National Independent Innovation Demonstration Zone ZJ2019-ZD-004
6 · The paper itself

Abstract

Immunotherapy has revolutionized cancer treatment, yet many patients show non-sensitivity. Here, we collected treatment-naïve samples from 190 esophageal squamous cell carcinoma (ESCC) patients undergoing anti-programmed death 1 (PD1) immunotherapy for proteome, phosphoproteome, and immunohistochemistry (IHC) analysis. Proteome-based stratification of ESCC identifies three proteomic subtypes (G-I-G-III) related to immunotherapy response and different molecular features, revealing that patients with high mitochondrial complex I protein expression show sensitivity to anti-PD1 immunotherapy. High mitochondrial complex I protein expression of ESCC cells or patient-derived organoids increases sensitivity to CD8 + T cell-mediated killing in the co-culture systems. Phosphoproteomic data analysis reveals YAP1 activation impairs immunotherapy efficacy. Inhibiting YAP1 or increasing mitochondrial complex I levels bolsters immunotherapy effectiveness in ESCC allograft tumors. Finally, we develop a highly accurate predictive model (AUC ≥ 0.90) by the signatures of mitochondrial complex I-mediated anti-tumor immune response and validate it in independent cohorts. This study provides a rich resource for investigating the mechanisms and indicators of immunotherapy in ESCC.

Indexed as

Electron Transport Complex IEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaImmunotherapyProteomeAnimalsCD8-Positive T-LymphocytesCell Line, TumorFemaleHumansMaleProgrammed Cell Death 1 ReceptorElectron Transport Complex IProgrammed Cell Death 1 ReceptorProteome

Identifiers

PMID41965870
PMCPMC13179373

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.